TRVI – trevi therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
Is Trevi Therapeutics (TRVI) Building a Multi-Indication Moat With Its Nalbuphine ER Cough Strategy? [Yahoo! Finance]
Trevi Therapeutics (TRVI) Valuation Check After FDA End Of Phase 2 Update And Renewed Analyst Optimism [Yahoo! Finance]
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $19.00 price target on the stock.
Form SCHEDULE 13G Trevi Therapeutics, Inc. Filed by: FMR LLC
Form SCHEDULE 13G Trevi Therapeutics, Inc. Filed by: VANGUARD GROUP INC
Form 4 Trevi Therapeutics, Inc. For: Jan 08 Filed by: HASTINGS DAVID C
Form 3 Trevi Therapeutics, Inc. For: Jan 08 Filed by: HASTINGS DAVID C
Form 8-K Trevi Therapeutics, Inc. For: Dec 01
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.